Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance

Lorenzo Falchi, MD, Michael Keating, MBBS, Susan Lerner, MS, Xuemei Wang, PhD, Kplola Y Elhor Gbito, MD MPH, Sara S. Strom, PhD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD

Blood (2014) 124 (21): 3323.

https://doi.org/10.1182/blood.V124.21.3323.3323

Published: 2014

Journal Articles

STAT3 Activates Anti-Apoptotic Genes But When In Access Induces Apoptosis Of CLL Cells

Rozovski Uri, MD, David Harris, Ping Li, PhD, Zhiming Liu, Ji Yuan, Srdana Grugurevic, Susan Lerner, MS, William G. Wierda, MD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2013) 122 (21): 5294.

https://doi.org/10.1182/blood.V122.21.5294.5294

Published: 2013

Journal Articles

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

Jan A. Burger, MD, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Julia Hoellenriegel, Ghayathri Jeyakumar, MD, Alessandra Ferrajoli, MD, Stefan H. Faderl, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Susan Lerner, MS, Gracy Zacharian, Xuelin Huang, Hagop M. Kantarjian, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 675.

https://doi.org/10.1182/blood.V122.21.675.675

Published: 2013

Journal Articles

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Jan A. Burger, MD, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Julia Hoellenriegel, Alessandra Ferrajoli, M.D., Stefan Faderl, MD, Susan Lerner, MS, Gracy Zacharian, Xuelin Huang, PhD, Danelle F. James, M.D., Joseph J. Buggy, PhD, Hagop M Kantarjian, Susan M. O'Brien

Blood (2012) 120 (21): 187.

https://doi.org/10.1182/blood.V120.21.187.187

Published: 2012

Journal Articles

Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia

Neil E. Kay, MD, Christopher R. Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Ian W. Flinn, MD, PhD, David Grinblatt, MD, Thomas J. Kipps, MD, PhD, Mark Kozloff, Susan Lerner, MS, Jeff Sharman, MD, Ren Yu, MA, Zeba M. Khan, PhD, Thomas K. Street, RPh, Arlene S. Swern, PhD, Kristen A. Sullivan, MBA, Chris L Pashos, PhD

Blood (2012) 120 (21): 3926.

https://doi.org/10.1182/blood.V120.21.3926.3926

Published: 2012

Journal Articles

Is Chronic Lymphocytic Leukemia Still Incurable?

Michael J. Keating, MD, Constantine S Tam, William G. Wierda, MD, Ph.D., Susan O'Brien, M.D., Deborah A. Thomas, MD, Jorge E. Cortes, MD, Susan Lerner, MS, William Plunkett, PhD

Blood (2012) 120 (21): 3929.

https://doi.org/10.1182/blood.V120.21.3929.3929

Published: 2012

Journal Articles

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Ohad Benjamini, MD, Xuemei Wang, MS, Susan Lerner, MS, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 3931.

https://doi.org/10.1182/blood.V120.21.3931.3931

Published: 2012

Journal Articles

Other Cancers in Patients with Chronic Lymphocytic Leukemia Requiring Therapy: Association with Prognostic Factors and Impact On Survival

Lorenzo Falchi, MD, Michael J. Keating, MD, Susan Lerner, MS, Xuemei Wang, MS, Sara S. Strom, PhD, William G. Wierda, MD, Alessandra Ferrajoli, M.D.

Blood (2012) 120 (21): 3896.

https://doi.org/10.1182/blood.V120.21.3896.3896

Published: 2012

Journal Articles

Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12

Paolo Strati, MD, Lynne V. Abruzzo, MD, PhD, William Wierda, MD, PhD, Susan Lerner, MS, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, M.D., Michael J. Keating, MD

Blood (2012) 120 (21): 3907.

https://doi.org/10.1182/blood.V120.21.3907.3907

Published: 2012

Journal Articles

Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)

Rozovski Uri, MD, David Harris, Ping Li, PhD, Zhiming Liu, Srdana Grgurevic, Susan Lerner, MS, Matthew Martinez, William G. Wierda, MD, Ph.D., Michael Keating, MD, Zeev Estrov, MD, PhD

Blood (2012) 120 (21): 3910.

https://doi.org/10.1182/blood.V120.21.3910.3910

Published: 2012

Journal Articles

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, M.D., Susan O'Brien, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, Michael J. Keating, MD, Varsha V. Gandhi, Ph.D.

Blood (2012) 120 (21): 437.

https://doi.org/10.1182/blood.V120.21.437.437

Published: 2012

Journal Articles

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Susan Lerner, MS, Ohad Benjamini, MD, Xuemei Wang, MS, Michael J. Keating, MD

Blood (2012) 120 (21): 2900.

https://doi.org/10.1182/blood.V120.21.2900.2900

Published: 2012

Journal Articles

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Preetesh Jain, MD, DM, PhD, Long Xuan Trinh, Ohad Benjamini, MD, Susan Lerner, MS, Xuemei Wang, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Zeev Estrov, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Lynne V. Abruzzo, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 2890.

https://doi.org/10.1182/blood.V120.21.2890.2890

Published: 2012

Journal Articles

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Lorenzo Falchi, MD, Long Xuan Trinh, Edith M. Marom, MD, Mylene Truong, MD, Ellen Schlette, MD, Rachel L. Sargent, MD, Xuemei Wang, MS, Susan C. Smith, Susan Lerner, MS, Michael J. Keating, MD, Alessandra Ferrajoli, MD

Blood (2012) 120 (21): 927.

https://doi.org/10.1182/blood.V120.21.927.927

Published: 2012

Journal Articles

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Xavier C Badoux, MBBS, Michael J Keating, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Zeev Estrov, Manolo Pasia, BSN, Susan Lerner, MS, BA, Rachel L Sargent, MD, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD

Blood (2011) 118 (21): 980.

https://doi.org/10.1182/blood.V118.21.980.980

Published: 2011

Journal Articles

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

Francesco Paolo Tambaro, MD, PhD, Guillermo Garcia-Manero, Stefan Faderl, MD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Long Xuan Trinh, Susan Lerner, MS, BA, Hagop M. Kantarjian, Michael J Keating, MD, William G. Wierda, MD, PhD

Blood (2011) 118 (21): 981.

https://doi.org/10.1182/blood.V118.21.981.981

Published: 2011

Journal Articles

Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect ® CLL Disease Registry

Jeff Sharman, MD, Christopher R Flowers, MD, Mark Weiss, MD, David Grinblatt, MD, Charles Farber, MD, PhD, Neil Kay, MD, Thomas Kipps, MD, Nicole Lamanna, MD, Chris Pashos, PhD, Ian W Flinn, MD, Mark Kozloff, MD, Susan Lerner, MS, Arlene S Swern, PhD, Kristen A Sullivan, MBA, Thomas K. Street, RPh, Michael Keating, MBBS

Blood (2011) 118 (21): 2864.

https://doi.org/10.1182/blood.V118.21.2864.2864

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Michael J Keating, MD

Blood (2011) 118 (21): 2085.

https://doi.org/10.1182/blood.V118.21.2085.2085

Published: 2011

Journal Articles

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, MD, Tapan Kadia, Jorge E. Cortes, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, BA, Michael J Keating, MD, Varsha Gandhi, PhD

Blood (2011) 118 (21): 3901.

https://doi.org/10.1182/blood.V118.21.3901.3901

Published: 2011

Journal Articles

Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,

William G. Wierda, MD, PhD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Charles Asa Koller, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, Tapan Kadia, Susan Lerner, MS, BA, Michael J Keating, MD

Blood (2011) 118 (21): 3902.

https://doi.org/10.1182/blood.V118.21.3902.3902

Published: 2011

NARROW

Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance

STAT3 Activates Anti-Apoptotic Genes But When In Access Induces Apoptosis Of CLL Cells

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia

Is Chronic Lymphocytic Leukemia Still Incurable?

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Other Cancers in Patients with Chronic Lymphocytic Leukemia Requiring Therapy: Association with Prognostic Factors and Impact On Survival

Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12

Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect ® CLL Disease Registry

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only